VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- November 08, 2006 -- Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced it had successfully completed patient enrolment in its Phase IIb trial with IPL512,602 for the treatment of moderate to severe asthma. This international study enrolled 218 subjects at centers in the US, Russia, Poland, Bulgaria and the Ukraine. The study began in May 2006 and it is on track to complete in Q1 2007 with top line results expected shortly thereafter.
